App-Quantinova.ai

Disease activity, comorbidities and functional status predict treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis

Christine Addae-Kyereme - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

A 24-month prospective psoriatic arthritis observational study of persistence of treatment - interim analysis of baseline characteristics

Jacques Morel - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

ABT-494

Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis refractory to biologic therapies: 2-year results from the phase 3 SELECT-PsA 2 study

Philip J Mease - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

ABT-494

Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis

Atul Deodhar - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Axial spondyloarthritis

LY2439821

Measurement of response to treatment in axial spondyloarthritis using quantitative imaging biomarkers: a prospective observational cohort study

Alexis Jones - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Bimekizumab in patients with psoriatic arthritis with prior inadequate response to TNF inhibitors: improvements of PsARC over 16 weeks in the Phase 3 BE COMPLETE trial

Poonam Sharma - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

bimekizumab

Poor mental health risk is associated with high disease activity in axial spondyloarthritis in the UK: results from the International Map of Axial Spondyloarthritis (IMAS)

Marco Garrido-Cumbrera - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16: results from COAST-V trial

Sofia Ramiro - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Adalimumab

What do patients value and need in the diagnosis, treatment and care of axial spondyloarthritis? Results from a quantitative study

Jill Hamilton - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies

Karl Gaffney - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

bimekizumab

Bimekizumab is associated with improvement in quality of life in patients across the full spectrum of axial spondyloarthritis at week 16: results from two phase 3 studies

Neil McKay - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

bimekizumab

Use of the Giant Cell Arteritis Score (GCAPS) in a district general hospital

Rosemary Waller - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

The changing role of biopsy and imaging in the diagnosis of giant cell arteritis prior to tocilizumab treatment

Lisa M M Hutton - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Tocilizumab

Evaluating the safety and factors associated with treatment cessation in Takayasu arteritis

Robert T Maughan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

Glucocorticoid

Glucocorticoid taper success after one and two years treatment in the Imperial College Takayasu Arteritis Cohort

Ritu Alapat - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

Glucocorticoid

Inactive Takayasu’s arteritis: a case series analysis of presentations to a tertiary vasculitis centre

Samuel Hanlon - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

N/A

Comparison of coding of giant cell arteritis in primary and secondary care records: an observational feasibility study

Nishita Padmanabhan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis

Noelle Pisacano - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Glomerulonephritis

Prednisolone

External validation of the Southend giant cell arteritis pre-test probability score in a Dorset fast-track clinic

James Carroll - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Large vessel vasculitis

N/A

PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population

Ben Mulhearn - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Aortic valve calcification

N/A

Filters

45280 Abstracts